ATE236156T1 - Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben - Google Patents

Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben

Info

Publication number
ATE236156T1
ATE236156T1 AT97924255T AT97924255T ATE236156T1 AT E236156 T1 ATE236156 T1 AT E236156T1 AT 97924255 T AT97924255 T AT 97924255T AT 97924255 T AT97924255 T AT 97924255T AT E236156 T1 ATE236156 T1 AT E236156T1
Authority
AT
Austria
Prior art keywords
derivatives
pct
cgmp
pyridocarbazole
pde
Prior art date
Application number
AT97924255T
Other languages
English (en)
Inventor
Masayuki Ohashi
Toshiyuki Shudo
Kazumi Nishijima
Tatsuto Notsu
Akira Kikuchi
Kazutoshi Yanagibashi
Hidemitsu Nishida
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE236156T1 publication Critical patent/ATE236156T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97924255T 1996-05-31 1997-05-29 Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben ATE236156T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16073196 1996-05-31
PCT/JP1997/001829 WO1997045427A1 (en) 1996-05-31 1997-05-29 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT

Publications (1)

Publication Number Publication Date
ATE236156T1 true ATE236156T1 (de) 2003-04-15

Family

ID=15721249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97924255T ATE236156T1 (de) 1996-05-31 1997-05-29 Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben

Country Status (8)

Country Link
US (2) US6018046A (de)
EP (1) EP0985671B1 (de)
KR (1) KR20000010919A (de)
AT (1) ATE236156T1 (de)
CA (1) CA2256889A1 (de)
DE (1) DE69720542D1 (de)
TW (1) TW422837B (de)
WO (1) WO1997045427A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
AU5067098A (en) * 1997-11-26 1999-06-15 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives with cgmp-pde inhibitory activity
ZA9810766B (en) 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
EP1136072A4 (de) * 1998-12-02 2004-12-15 Mochida Pharm Co Ltd Zubereitung zur verabreichung in den harnleiter
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
TWI222450B (en) 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US6932961B1 (en) 2002-04-16 2005-08-23 Pharmacia & Upjohn Company Oxazinocarbazoles for the treatment of CNS diseases
JP2005535607A (ja) * 2002-06-10 2005-11-24 モンドバイオテック・ラボラトリーズ・アンスタルト サルコイドーシスを治療するための血管作動性腸管ペプチドの生物活性をもつ化合物の使用
ES2334682T3 (es) * 2004-03-05 2010-03-15 Nycomed Gmbh Nuevo uso para inhibidores de pde5.
US7662831B2 (en) * 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
FR2934595B1 (fr) * 2008-07-29 2013-04-05 Biomerieux Sa Reactifs de marquage ayant un noyau pyridine portant une fonction diazomethyle, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
EP2887803A4 (de) 2012-08-24 2016-08-03 Univ Texas Pro-neurogene verbindungen
US10396294B2 (en) 2013-12-27 2019-08-27 Samsung Electronics Co., Ltd. Carbazole compound and organic light-emitting device including the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
KR20000010919A (ko) 2000-02-25
WO1997045427A1 (en) 1997-12-04
DE69720542D1 (de) 2003-05-08
EP0985671A4 (de) 2001-07-25
EP0985671A1 (de) 2000-03-15
TW422837B (en) 2001-02-21
US6018046A (en) 2000-01-25
US6197768B1 (en) 2001-03-06
EP0985671B1 (de) 2003-04-02
CA2256889A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
DE69720542D1 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
ES2161785T3 (es) Emplasto para el tratamiento de micosis ungulares.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
NO976048D0 (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
ATE226436T1 (de) Neue verwendung von dexmedetomidin
NO20001483L (no) Nye NPY-agonister
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DK0888327T3 (da) Benzopyranderivater, som har antagonistisk virkning imod leukotriener
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
BR9815070A (pt) Compostos tendo efeito inibitório da cgmp-pde
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
ATE267816T1 (de) Tan-1057 derivate
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE254472T1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı
BR9608038A (pt) Fenilamidinas substituídas compostos que contêm estes medicamentos e processo para sua preparação
ATE172118T1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
BG101407A (bg) Пиролил-тетрахидробензохиноксалиндиони, метод за получаването им и използването им като глутамат- рецепторни антагонисти
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties